Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer

H Ozen1

  • 1Department of Urology, Hacetteppe University, Faculty of Medicine, Ankara, Turkey.

Current Opinion in Oncology
|June 10, 1998
PubMed
Summary
This summary is machine-generated.

Genetic alterations in bladder cancer, including chromosome 9 loss and p53/pRb mutations, impact tumor progression and survival. Altered p53 predicts chemotherapy response and tumor aggressiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new adjacent tool in the management of clinical T1a solid renal masses.

Actas urologicas espanolas·2026
Same author

Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation.

International journal of laboratory hematology·2016
Same author

Successful outcome with second hematopoietic stem cell transplantation in a patient with IL-10R deficiency.

Bone marrow transplantation·2015
Same author

Is routine stenting necessary in pyeloplasty?

Pediatric surgery international·2013
Same author

Can p53, Ki-67 and bcl-2 predict biochemical failure after radical prostatectomy?

Indian journal of urology : IJU : journal of the Urological Society of India·2010
Same author

Pathological, biochemical and haematological investigations on the protective effect of alpha-lipoic acid in experimental aflatoxin toxicosis in chicks.

British poultry science·2010
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Bladder cancer research is rapidly identifying genetic alterations.
  • Loss of heterozygosity on chromosome 9 is a common finding, suggesting tumor suppressor genes.
  • p53 and pRb gene alterations are linked to bladder cancer progression and patient survival.

Purpose of the Study:

  • To investigate the role of genetic alterations in bladder cancer.
  • To understand the prognostic significance of p53 and pRb in bladder cancer.
  • To explore the implications of these genetic findings for treatment strategies.

Main Methods:

  • Analysis of genetic alterations, including loss of heterozygosity on chromosome 9.
  • Assessment of p53 and pRb gene status and expression.

Related Experiment Videos

  • Correlation of genetic markers with tumor progression, survival, and treatment response.

    • Main Results:

    • Loss of heterozygosity on chromosome 9, particularly 9q, may represent an early event in bladder cancer development.
    • Alterations in both p53 and pRb genes are associated with more aggressive disease and poorer survival.
    • p53 alterations correlate with reduced recurrence risk and improved survival in patients receiving adjuvant chemotherapy.
    • Radiation combined with radiosensitizing agents shows efficacy in tumor reduction and local control for selected patients.

    Conclusions:

    • Genetic profiling, especially of p53, can predict bladder cancer aggressiveness and identify patients who may not benefit from chemotherapy.
    • Targeted molecular therapies informed by genetic alterations hold promise for personalized treatment of bladder cancer.
    • Further molecular genetics research is crucial for refining treatment selection in bladder cancer.